On February 14, Zhuhai Livanda Biotechnology Co., Ltd. (“Livanda”) announced that the first batch of standard samples of mRNA new coronavirus vaccine, which was completed during the Spring Festival, had been delivered to the relevant state authorities for animal testing and drug efficacy verification on February 1. On the 13th, in a single 12-day immune serum, the researchers detected the production of target antibodies. It is also the first time a new coronavirus vaccine based on mRNA technology has tested positive antibodies in animals worldwide, the company said.
Recently, Livanda made a breakthrough in the development of the new coronal pneumonia vaccine. One is that in the cell level verification, in the company’s parallel efficacy evaluation, the researchers again at the cell level to verify the expression of antigens at multiple targets. In an animal trial, researchers detected the production of target antibodies in a single 12-day-old mouse serum.
“The production of antibodies in animals is a positive sign that the vaccine works, but whether these antibodies can ‘eliminate’ the virus also needs to be finally verified through virus neutralizing testing and attack testing, and we are accelerating this process.” Several mRNA technology companies, including Moderna, the United States, are also working with relevant government health agencies to develop a new coronary pneumonia vaccine, said Dr. Peng Yucai, founder of Lifanda and a leader in Guangdong Province. Livanda is currently working with the Academy of Military Medical Sciences, the Guangdong Provincial Institute of Corrections and the Macao University of Science and Technology to advance the project quickly. The antigens used in its development are consistent with that of Moderna USA.
Livanda is registered in Zhuhai Hengqin Guangdong-Australia Cooperative Chinese Medicine Science and Technology Industry Park, with independent mRNA production and drug delivery platform. Its mRNA technology research and development began in 2017 and has applied for a number of patents for inventions in drug design, production and preparation delivery. The company has accumulated a lot of experience in vaccine development, its research and development of the fastest-growing mRNA rabies vaccine project, is currently in the preclinical research stage.
In addition to mice, the mRNA new coronavirus vaccine developed by Livanda is also being tested in large mammals such as monkeys, with results in one to two weeks. Peng Yucai said the new coronavirus vaccine developed by his team is expected to enter the clinical phase within 2-3 months.
In addition, Livanda is preparing for subsequent GMP-grade commercial production. In partnership with the Liju Group, Livanda has the ability to produce clinically and commercially available vaccines quickly, with production times as short as 1-2 days per batch. Its new GMP plant in Hengqin New Area Guangdong-Australia Cooperative Chinese Medicine Science and Technology Industrial Park, which could be put into use as early as April this year.